Posted by Michael Wonder on 29 Aug 2024
Life Molecular Imaging receives FDA fast track designation for [18F]PI-2620 in Tau PET imaging across three neurodegenerative conditions
28 August 2024 - Life Molecular Imaging is pleased to announce that the US FDA granted fast track designation to [18F]PI-2620 injection, an investigational PET imaging agent targeting tau neurofibrillary tangles.
The fast track designation has been granted for clinical development in Alzheimer's disease, progressive supranuclear palsy and corticobasal degeneration.
